Clinical trials: Tumor Microenvironment
Cutaneous Malignant Melanoma
Electrochemotherapy Changes in Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Melanoma Patients
In the last 10 years, the treatment of metastatic cutaneous melanoma has changed dramatically. The new systemic treatment with immunotherapy has led to a dramatic improvement in quality of life and overall survival.
- Trial name
- NCT06388252
- Testing
- Electrochemotherapy with Intratumoral Cysplatin, Electrochemotherapy with Intravenous Bleomycin
- Where
- Slovenia
- Volunteers
- 10 people
- Sponsor
- Institute of Oncology Ljubljana
Squamous Cell Carcinoma
Study of the Association Between Tumor Microenvironment Macrophages and Treatment Response in Squamous Cell Carcinoma of the Anal Canal
Squamous cell carcinoma of the anal canal is a relatively rare cancer (less than 3% of digestive cancers) but its incidence has been increasing in recent decades, probably because of its association with HPV (human…
- Trial name
- MACARAN (NCT05019235)
- Where
- France
- Volunteers
- 154 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Prostate Cancer
AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)
The goal of this clinical research study is learn how AMG208 may help to control prostate cancer that has spread to the bone. The safety of the drug will also be studied.
- Trial name
- NCT02420587
- Testing
- AMG 208, Questionnaire
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment
Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer
This pilot study aims to trial multimodal early response assessment to enable therapy adaptions in the context of non-operative therapy strategies of locally advanced rectal cancer (LARC) for development of a non-invasive…
- Conditions
- Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment, Radiotherapy, Adaptive Treatment
- Trial name
- PRIMO (NCT05524012)
- Testing
- Blood sample, MRI scan
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Jena University Hospital
Urologic Cancer
Exploring the Association of Imaging and Tumor Microenvironment in Urologic Cancer Using Radiogenomic Approach（Radiogenomics-Urinary）
This is the prospective, observational cohort study (Radiogenomics-Urinary), which aims to explore the relationship between the imaging information of urologic cancer patients, tumor microenvironment and the prognosis of urologic…
- Trial name
- NCT06537037
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma, To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer
Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of fruquintinib and pirfenidone in combination with anti-PD-1 antibody in patients with standard treatment failure of advanced or metastatic pMMR/MSS colorectal…
- Conditions
- To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma, To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer, Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer
- Trial name
- NCT06484153
- Testing
- Pirfenidone, Fruquintinib, Pembrolizumab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
High Grade Serous Ovarian Cancer
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
The objective of this study is to explore the integration of in vivo and ex vivo of MRI with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high-grade serous ovarian cance
- Trial name
- MR-O-MICS (NCT06084195)
- Testing
- Blood sample and tissue sample
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Colorectal Cancer, Pancreas Tumor
Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort
Colorectal and pancreatobiliary cancers are the most common digestive cancers. Their incidence has particularly increased over the last few decades, leading to suspicion that environmental factors are involved.
- Conditions
- Colorectal Cancer, Pancreas Tumor, Biliary Tract Tumor, Immune System and Related Disorders
- Trial name
- MICADO (NCT04707365)
- Testing
- Tumor samples
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immunotherapy
Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy
Colorectal cancer (CRC) ranks as the fifth most common malignant tumor in the Chinese population. In current clinical practice, standard first- and second-line treatments for metastatic microsatellite-stable (MSS)/proficient…
- Trial name
- NCT06946745
- Testing
- tissue biopsy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- jianming xu
Hepatocellular Carcinoma
Prospective Cohort Study on the Clinical Trajectory of Resected Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 6th most common cancer in the world but the 2nd most important cause of cancer death. Because of its highly heterogeneous nature, the current approach to identifying druggable targets have…
- Trial name
- PLANET (NCT03267641)
- Where
- 6 sites in Malaysia, Philippines and 2 more
- Volunteers
- 86 people
- Sponsor
- National Cancer Centre, Singapore
Melanoma
EF5 in Melanoma Patients
The purpose of this pilot study is to determine the prevalence of markers of chronic and cycling hypoxia and reactive species stress (oxidative and nitrosative) in the melanoma tumor microenvironment.
- Trial name
- NCT01752257
- Testing
- EF5 Hypoxia
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Douglas Tyler
Lung Cancer, NSCLC
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)
Lung cancer is one of the most common and serious types of cancer. Lung tumor cells exploit immune checkpoint proteins (ICPs) to maintain immune tolerance and thus promote tumor progression and invasion.
- Trial name
- NCT06502249
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Neoplasms, Immunotherapy
IMMUNO-FIT Observational Study
This observational study will investigate how immunotherapy affects physical fitness, quality of life, and treatment tolerance in adults with solid cancers.
- Conditions
- Neoplasms, Immunotherapy, Physical Fitness, Quality of Life
- Trial name
- NCT07354971
- Testing
- Observational Study - No Study Intervention
- Where
- United Kingdom
- Volunteers
- 67 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Cancer
Particle-based Partial Tumor Irradiation of Unresectable Bulky Tumors
This study uses a novel, recently developed unconventional radiotherapy technique which consists of three high-dose fractions directed to special segments of unresectable bulky tumors.
- Trial name
- PARTICLE-PATHY (NCT04875871)
- Testing
- Particle radiotherapy, Magnetic resonance imaging, Computertomography
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- EBG MedAustron GmbH
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT06694454
- Testing
- azacytidine, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use
This trial studies how well an enhanced tobacco intervention protocol (ETIP) works compared to standard treatment in helping head and neck and lung cancer patients starting treatment to reduce cigarette use.
- Trial name
- NCT04694846
- Testing
- Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Thomas Jefferson University
Meningioma
Role of the Tumor Microenvironment in Aggressive Meningiomas
Meningiomas are the most common primary tumors of the central nervous system in adults. High-grade forms have a high frequency of neurofibromatosis 2 (NF2) mutations and represent 25% of meningiomas, with multiple recurrences…
- Trial name
- MEME (NCT05821790)
- Testing
- Surgical waste and Data collect
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Metastatic Pancreatic Cancer
Proglumide and Chemotherapy for Metastatic Pancreatic Cancer
This is a Phase 2 study with an open labelled lead-in study to approximately treat 30 patients [6 subjects for Lead-in and 24 for Phase 2] enrolled with metastatic pancreatic cancer with combination therapy using standard of care…
- Trial name
- ProGem (NCT05827055)
- Testing
- Gemcitabine, Nab paclitaxel, Proglumide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Georgetown University
Liver Cancer
Exploring the Association of Imaging and Tumor Microenvironment in Liver Cancer Using Radiogenomic Approach（Radiogenomics-Liver）
This is the prospective, observational cohort study (Radiogenomics-Liver), which aims to explore the relationship between the imaging information of liver cancer patients, tumor microenvironment and the prognosis of liver cancer…
- Trial name
- NCT06536998
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Glioblastoma
Evaluation of in Vitro Antitumor Activity of GD2 CAR-T Cells in Glioblastoma
Glioblastoma is a brain tumor with a very poor prognosis, affecting around 2,400 new patients every year. Current treatments do not provide good control of the disease.
- Trial name
- BOOSTCAR (NCT06764537)
- Testing
- Blood collection
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Central Hospital, Nancy, France